Rare Frequency of Mutations in Pituitary Transcription Factor Genes in Combined Pituitary Hormone or Isolated Growth Hormone Deficiencies in Korea

Jin-Ho Choi¹, Chang-Woo Jung², Eungu Kang³, Yoon-Myung Kim¹, Sun Hee Heo¹, Beom Hee Lee¹, Gu-Hwan Kim³, and Han-Wook Yoo¹

¹Department of Pediatrics, ²Asan Institute for Life Sciences, and ³Medical Genetics Center, Asan Medical Center Children’s Hospital, University of Ulsan College of Medicine, Seoul, Korea.

**Purpose:** Congenital hypopituitarism is caused by mutations in pituitary transcription factors involved in the development of the hypothalamic-pituitary axis. Mutation frequencies of genes involved in congenital hypopituitarism are extremely low and vary substantially between ethnicities. This study was undertaken to compare the clinical, endocrinological, and radiological features of patients with an isolated growth hormone deficiency (IGHD) or combined pituitary hormone deficiency (CPHD).

**Materials and Methods:** This study included 27 patients with sporadic IGHD and CPHD. A mutation analysis of the POU1F1, PROP1, LHX3, LHX4, and HESX1 genes was performed using genomic DNA from peripheral blood leukocytes.

**Results:** IGHD and CPHD were observed in 4 and 23 patients, respectively. Mean age at diagnosis was 8.28±7.25 years for IGHD and 13.48±10.46 years for CPHD (p=0.37). Serum insulin-like growth factor-1 and peak growth hormone (GH) levels following GH stimulation tests were significantly lower in patients with CPHD than in those with IGHD (p<0.05). Sellar MRI findings revealed structural abnormalities in 3 patients with IGHD (75%) and 21 patients with CPHD (91.3%) (p=0.62). A mutation analysis identified homozygous p.R109Q mutations in HESX1 in a patient with CPHD. Patients with CPHD had more severe GHD than those with IGHD.

**Conclusion:** The frequency of defects in the genes encoding pituitary transcription factors was extremely low in Korean patients with congenital hypopituitarism. Environmental factors and the impact of other causative genes may contribute to this clinical phenotype.

**Key Words:** Combined pituitary hormone deficiency, HESX1, isolated growth hormone deficiency

**INTRODUCTION**

Congenital hypopituitarism is the deficiency of one or more anterior pituitary hormones,¹ manifested either as an isolated growth hormone deficiency (IGHD) or combined pituitary hormone deficiencies (CPHD) when two or more pituitary hormones are affected.¹² CPHD rarely occurs, at an estimated incidence of 1:8000 births, and is generally sporadic, although nearly 5–30% of all cases are familial.¹ Congenital hypopituitarism can be caused by mutations in pituitary transcription factor genes involved in the anterior pituitary development and the hypothalamic-pituitary axis, leading to inherited forms of these disorders.⁴

Pituitary transcriptional factors are part of the homeobox gene family and are key regulators of the multistep process for morphogenesis and organogenesis of the pituitary gland. This involves highly complex developmental steps in a temporally-and spatially-specific manner. At the level of the anterior pituitary gland, mutations in the genes encoding key transcription factors, hypothalamic releasing and inhibiting hormones or receptors, and the pituitary hormones themselves can all result in...
the loss of action of one or more of the specialized hormone-secreting cell types. Several pituitary transcription factor genes have been linked to the proliferation and terminal differentiation of the anterior pituitary gland, including *POUIF1*, *PROP1*, *LHX3*, *LHX4*, *OTX2*, *SOX2*, *SOX3*, *GLI2*, and *HESXI*. The clinical phenotype of congenital hypopituitarism has been found to be associated with structural abnormalities of the hypothalamus and pituitary gland. The expression patterns of the pituitary transcription factors exhibit a phenotype when gene encoding the relevant transcription factor becomes mutated. The phenotype of subjects carrying mutations within transcription factors involving early pituitary organogenesis may lead to extrapituitary manifestations [e.g., septo-optic dysplasia (SOD) or holoprosencephaly in the case of *HESXI* or *GLI2* mutations, respectively]. Other extrapituitary manifestations (e.g., Chiari malformation, corpus callosum agenesis or hypoplasia, hearing loss, and skeletal abnormalities) are associated with *LHX3* and *LHX4* mutations. In contrast, *POUIF1* and *PROP1* are late-acting transcription factors, involving terminal cell differentiation. Mutations in these genes generate a pituitary-specific phenotype that is characterized by multiple hormone deficiencies without relevant extrapituitary phenotypes. Mutation frequencies of genes involved in CPHD are low and vary substantially between ethnicities. Our group reported on a mutation analysis of the *POUIF1*, *PROP1*, *LHX3*, and *HESXI* genes in a limited number of patients and showed that the mutation frequency of pituitary transcription factor genes is extremely small. This study was undertaken to compare the clinical, endocrinological, and radiological features of patients with IGHD or CPHD and to investigate the frequency of mutations in the most relevant transcription factor genes (i.e., *POUIF1*, *PROP1*, *LHX3*, *LHX4*, and *HESXI*) in a relatively large cohort of Korean patients with CPHD and IGHD.

**Materials and Methods**

Subjects
This study included 27 unrelated patients (16 males, 11 females) with IGHD or CPHD. The following parameters were analyzed retrospectively: age at diagnosis, height, weight, perinatal history, family history, combined anterior pituitary function tests, and sellar magnetic resonance imaging (MRI) findings.

Diagnosis of IGHD or CPHD was based on history, auxological data, hormonal investigations, and neuroradiological imaging. GHD and a deficiency of one or more of the other anterior pituitary hormones constituted the criteria for the diagnosis of CPHD. Patients with acquired hypopituitarism caused by a brain tumor, cranial irradiation, inflammation, or trauma were excluded. This study was approved by the Institutional Review Board at the Asan Medical Center, Korea, and informed consent was obtained from all patients or parents.

Endocrinological evaluation
Pharmacological growth hormone (GH) stimulation was tested using the levodopa (125–500 mg) and insulin tolerance tests (regular insulin 0.1 U/kg). A combined anterior pituitary function test was also performed using combined infusion of regular insulin (0.1 U/kg), gonadotropin-releasing hormone (Relefact), Sanofi-Aventis, Frankfurt, Germany; 60 μg/m²), and thyrotropin-releasing hormone (TRH; Preline®, Ferring Pharmaceuticals Ltd., Kiel, Germany; 250 μg/m²). Basal and stimulated levels of GH, adrenocorticotropic hormone (ACTH), cortisol, thyroid stimulating hormone (TSH), prolactin (PRL), luteinizing hormone (LH), and follicle-stimulating hormone (FSH) were determined at sequential time points (15, 30, 60, 90, and 120 min post-stimulation). GH was measured using a monoclonal immunoradiometric assay (IRM); Diagnostics Systems Laboratories, Inc., Webster, TX, USA). Measurements of insulin-like growth factor (IGF)-1 and IGF binding protein-3 levels were conducted using IRMA (Immunotech, Marseilles, France). All other hormones were also assayed by IRMA.

A peak GH level below 7 ng/mL in two separate tests was regarded as GHD, and TSH deficiency was diagnosed on the basis of a free T4 level less than 0.9 ng/dL in combination with an inappropriately low serum TSH level (<5 mU/L). An ACTH deficiency was diagnosed based on a basal cortisol level of less than 5 μg/dL and a peak cortisol level of less than 18 μg/dL, correlated with a failure to increase ACTH levels. Hypogonadotropic hypogonadism was defined as delayed, or absent, pubertal development with low serum testosterone or estradiol levels, as well as a blunted LH/FSH response to GnRH stimulation. A PRL deficiency was defined as abnormal PRL levels during random or TRH stimulation tests. Bone age was assessed using the Greulich-Pyle method.

Mutation analysis of the pituitary transcription factor genes
Genomic DNA was extracted from peripheral blood leukocytes using a Puregene DNA isolation kit (Gentra, Minneapolis, MN, USA). Direct sequencing of the *POUIF1*, *PROP1*, *LHX3*, *LHX4*, and *HESXI* genes was performed using genomic DNA from peripheral blood leukocytes. All coding exons and exon-intron boundaries of the genes were individually amplified by polymerase chain reaction (PCR) using primers designed from the flanking regions of each gene. Amplified PCR products were directly sequenced using the BigDye Terminator v.3.1 Cycle Sequencing Kit (Applied Biosystems, Foster City, CA, USA) and ABI3130x1 Genetic Analyzer (Applied Biosystems, Foster City, CA, USA).

Statistical analysis
Data are expressed as the mean ± standard deviation (SD), and the statistical analyses were performed using SPSS version 21.0 for Windows (SPSS Inc., Chicago, IL, USA). Height and weight are expressed as standard deviation scores (SDSs) us-
The Mann-Whitney U test was used for a comparison between IGHD and CPHD patients. p values less than 0.05 were considered statistically significant.

### RESULTS

#### Clinical, endocrinological, and radiological features

IGHD was observed in 4 patients (1 male, 3 females), and CPHD in 23 patients (16 males, 7 females).

| Characteristic | IGHD (n=4) | CPHD (n=23) | p value |
|----------------|------------|-------------|---------|
| Male:female    | 1:3        | 16:7        | 0.17    |
| Age at diagnosis, yr | 8.28±7.25 (0.2–16.9) | 13.48±10.46 (0.2–35) | 0.37 |
| Height at diagnosis, SDS | -3.15±0.44 | -3.54±1.10 | 0.39 |
| IGF-1, ng/mL   | 44.48±29.36 (9.6–76.7) | 10.92±9.73 (1.0–35.7) | 0.047* |
| Peak GH, ng/mL | 2.96±2.69 (0.83–6.9) | 0.52±0.65 (0.1–2.6) | 0.002* |
| Breech delivery (%) | 0 (0) | 10 (43) | 0.19 |
| Complete GHD (%) | 3 (75) | 23 (100) | 0.15 |
| Abnormal sellar MRI findings (%) | 3 (75) | 21 (91.3) | 0.62 |
| Optic nerve hypoplasia (%) | 1 (25) | 5 (21.7) | 0.92 |

IGF-1, insulin-like growth factor-1; MRI, magnetic resonance imaging; IGHD, isolated growth hormone deficiency; CPHD, combined pituitary hormone deficiency; SDS, standard deviation score.

*Statistically significant.

#### Table 1. Comparison of Clinical, Endocrinological, and Radiologic Findings between Patients with IGHD or CPHD

**Table 2.** Sellar Magnetic Resonance Image (MRI) Findings, Hormone Deficiencies, and Mutation Analysis for Patients with Isolated Growth Hormone Deficiency or Combined Pituitary Hormone Deficiency

| No. | Breech presentation | Height-SDS | Hormone deficiency | MRI finding | Mutation* |
|-----|---------------------|------------|-------------------|-------------|-----------|
| 1   | No                  | -3.0       | GH                | EPP         | No        |
| 2   | No                  | -2.92      | GH                | Normal      | No        |
| 3   | No                  | -2.88      | GH                | Hypoplasia  | No        |
| 4   | No                  | -3.71      | GH                | EPP         | No        |
| 5   | No                  | -1.92      | GH, TSH, LH/FSH, ACTH | PSIS, hypoplasia | No |
| 6   | No                  | -1.06      | GH, TSH, ACTH     | SOD         | No        |
| 7   | No                  | -5.09      | GH, TSH, LH/FSH, ACTH | Normal      | No        |
| 8   | No                  | -2.2       | GH, TSH, LH/FSH, ACTH | Empty sella | No        |
| 9   | Yes                 | -4.05      | GH, LH/FSH        | PSIS        | No        |
| 10  | No                  | -5.73      | GH, TSH, LH/FSH, ACTH, ADH | SOD, hypoplasia | No |
| 11  | No                  | -3.56      | GH, TSH, LH/FSH, ACTH | PSIS, hypoplasia | No |
| 12  | Yes                 | -4.25      | GH, TSH, LH/FSH   | PSIS, hypoplasia | No |
| 13  | Yes                 | -3.75      | GH, TSH, LH/FSH, ACTH | EPP         | No        |
| 14  | Yes                 | -3.82      | GH, LH/FSH, ACTH  | Hypoplasia  | No        |
| 15  | No                  | -3.29      | GH, TSH, ACTH     | Normal      | No        |
| 16  | Yes                 | -1.07      | GH, TSH, LH/FSH, ACTH | EPP         | No        |
| 17  | No                  | -2.19      | GH, TSH, LH/FSH, ACTH | Aplasia     | No        |
| 18  | No                  | -0.06      | GH, TSH, LH/FSH, ACTH | PSIS, hypoplasia | No |
| 19  | Yes                 | -3.86      | GH, TSH, LH/FSH, ACTH, ADH | PSIS, hypoplasia | No |
| 20  | Yes                 | -4.77      | GH, TSH, ACTH     | EPP, hypoplasia | No |
| 21  | No                  | -4.42      | GH, TSH, ACTH     | EPP, hypoplasia | No |
| 22  | No                  | -3.41      | GH, LH/FSH, ACTH  | EPP, hypoplasia | No |
| 23  | No                  | -1.56      | GH, TSH, ACTH     | EPP         | No        |
| 24  | Yes                 | -2.85      | GH, TSH, LH/FSH, ACTH | PSIS        | No        |
| 25  | Yes                 | -3.14      | GH, TSH, LH/FSH   | PSIS        | No        |
| 26  | Yes                 | -4.33      | GH, TSH, LH/FSH, ACTH | hypoplasia | No |
| 27  | No                  | -2.8       | GH, ADH           | SOD         | No        |

EPP, ectopic posterior pituitary; SOD, septo-optic dysplasia; PSIS, pituitary stalk interruption syndrome; SDS, standard deviation score; GH, growth hormone; TSH, thyroid stimulating hormone; LH, luteinizing hormone; FSH, follicle-stimulating hormone; ACTH, adrenocorticotropic hormone; ADH, antidiuretic hormone.

*POU1F1, PROP1, LHX3, LHX4, and HESX1 genes.
CPHD was observed in 23 patients (16 males, 7 females). Age at diagnosis was 8.28±7.25 years (range: 0.2–16.9 years) for IGHD patients and 13.48±10.46 years (range: 0.2–35 years) for CPHD patients (p=0.37) (Table 1). Height-SDS at diagnosis was -3.15±0.44 for IGHD and -3.54±1.10 for CPHD (p=0.39). Breech presentation at birth was documented in 10 patients with CPHD (43%), whereas it was not found in IGHD patients. There was no family history of congenital hypopituitarism in any patient.

Endocrine characteristics, sellar MRI findings, and a molecular analysis of each patient are summarized in Table 2. Serum IGF-1 levels were 44.48±29.36 ng/mL (9.6–76.7 ng/mL) for IGHD and 10.92±9.73 ng/mL (1.0–35.7 ng/mL) for CPHD (p=0.047). The peak GH levels following GH stimulation tests were 2.96±2.69 ng/mL (0.83–6.9 ng/mL) for IGHD and 0.52±0.65 ng/mL (0.1–2.6 ng/mL) for CPHD (p=0.002) (Table 1).

In CPHD patients, endocrine dysfunctions other than GHD included central hypothyroidism in 19 patients (82.6%), ACTH deficiency in 18 patients (78.3%), hypogonadotropic hypogonadism in 17 patients (73.9%), and central diabetes insipidus in 3 patients (13.0%).

The sellar MRI findings demonstrated structural abnormalities in 3 patients with IGHD (75%) and 21 patients with CPHD (91.3%) (p=0.62). In the IGHD group, pituitary hypoplasia was observed in one patient, and an ectopic posterior pituitary was found in two patients. In the CPHD group, pituitary hypoplasia was found in 11 patients, pituitary stalk interruption syndrome in 9 patients, ectopic neurohypophysis in 6 patients, SOD in 3 patients, and empty sella syndrome in 1 patient.

Molecular analysis of pituitary transcription factor genes
Mutation analysis identified homozygous c.326G>A (p.R109Q) mutations in the *HESX1* gene in subject 21 with CPHD (Fig. 1, Table 2), reported to be pathogenic by an *in vitro* functional analysis. This patient was born after 37 weeks of gestation and had a birth weight of 2.56 kg (-1.77 SDS) after an uncomplicated pregnancy and delivery. She presented with a short stature at the age of 2.8 years. The height and weight at diagnosis were 77.5 cm (-4.16 SDS) and 8.6 kg (-4.56 SDS), respectively. Physical examination revealed a prominent forehead and small chin, while a combined anterior pituitary function test demonstrated GHD, ACTH deficiency, and central hypothyroidism. Brain MRI revealed an ectopic posterior pituitary and anterior pituitary hypoplasia, while optic nerve hypoplasia was not evident. The parents were non-consanguineous and phenotypically normal; the father was 179-cm tall (0.99 SDS) and the mother was 165-cm tall (0.83 SDS). Both parents were heterozygous carriers of a p.R109Q mutation in *HESX1*. No mutation was identified in the *POUIF1*, *PROP1*, *LHX3*, *LHX4*, and *HESX1* genes in the other patients.

**DISCUSSION**

This study described the clinical and endocrinological features of patients with IGHD and CPHD and demonstrated that mutation frequencies of the *POUIF1*, *PROP1*, *LHX3*, *LHX4*, and *HESX1* genes are rare in sporadic cases of congenital hypopituitarism in Korea. There were no significant differences in sex, age at diagnosis, height, weight, breech presentation, pituitary gland abnormalities, and optic nerve hypoplasia between patients with IGHD or CPHD. However, serum IGF-1 and peak GH levels after the GH stimulation tests were significantly lower in patients with CPHD than in those with IGHD (p<0.05) (Table 1).

Although the effects of these transcription factors in pituitary development are well-defined, neuroanatomy as delineated by neuroimaging in patients with and without genetic hypopituitarism can be highly variable. In a previous report, abnormal sellar MRI findings were more frequently found in CPHD than in IGHD cases. However, the present study showed that the frequency of structural abnormalities in the pituitary gland was not significantly different between IGHD and CPHD patients and that structural abnormalities were not related to the severity of GHD.

This study identified that only one CPHD patient without SOD phenotypes harbored homozygous p.R106Q mutations in the *HESX1* gene. This mutation was reported to abrogate DNA-binding ability and was unable to repress *PROP1*-mediated activation. Arginine 109 is located in the homeobox domain, critical for binding to target DNA sequences, and is a highly evolutionarily conserved region. The parents of this patients, who carried the same mutation in a heterozygous state, were of normal adult height and clinically normal. However, the heterozygous p.R109Q mutation in *HESX1* was identified in a patient with CPHD without SOD phenotypes. Variable penetrance of the p.R109Q mutation in *HESX1* suggests that the
impact of other genes in pituitary development or environmental factors can influence the clinical phenotype.

The *HESX1* gene is essential for forebrain development and is one of the earliest transcription factors involved in pituitary organogenesis. Indeed, *HESX1* has been shown to function as a repressor of *PROP1*-mediated gene stimulation, and 23 mutations in this gene have been identified to date (http://www.hgmd.org). The human *HESX1* mutation was first reported in sibling cases of CPHD with SOD and agenesis of the corpus callosum in the homozygous state, while subsequently, heterozygous *HESX1* mutations were shown to be associated with CPHD or IGHD, with or without SOD. Interestingly, homozygous mutations in *HESX1* are implicated in SOD in both humans and animal models, whereas heterozygous mutations were found to cause a wide spectrum of congenital hypopituitarism and midline defects with variable penetrance across families. These include unaffected mutation carriers and milder phenotypes, consistent with haploinsufficiency of the *HESX1* protein.

The endocrine phenotypes of the *POU1F1*, *HESX1*, *PROP1*, *LHX3*, and *LHX4* mutations tend to overlap, and these mutations are associated with variable degrees of anterior pituitary hormone deficiency (ranging from IGHD to the complete failure of all five anterior pituitary cell lineages). This complex phenotype is further complicated by the evolution of the hormonal make-up over the lifespan of the patient. Therefore, a detailed endocrine investigation at the time of diagnosis is not sufficient to suggest specific genetic screening. Pituitary transcription factor genes should be investigated in CPHD patients with specific conditions and/or extrapituitary findings, e.g., SOD for *HESX1*, limited neck rotation and sensorineural hearing loss for *LHX3*, and poorly developed sella turcica for *LHX4*. An algorithm was suggested to look for the candidate genes for CPHD, although no genetic defects have been established in most CPHD patients, because of a wide range of phenotypes. The most significant indication for genetic screening of CPHD is a family history of CPHD.

The advent of next-generation sequencing technologies has greatly reduced sequencing costs and significantly increased throughput, allowing for simultaneous analysis of several genes in singularly targeted platforms. In future studies, it would be worthwhile to consider the use of targeted platforms containing all pituitary transcription factor genes to improve the mutation detection rate and to detect multiple mutations in cases of oligogenic inheritance.

Environmental factors may also contribute to the variability of phenotypes. A causal relationship between gestational-perinatal complications and hypopituitarism has been suggested. However, it is difficult to differentiate whether perinatal insults (e.g., breech delivery) lead to hypopituitarism via a traumatic disruption of the pituitary stalk or whether hypopituitarism with structural hypothalamic-pituitary defects results in an increased prevalence of perinatal complications.

The frequency of mutations in sporadic patients with CPHD was much lower than that in familial patients. Mutation frequencies in genes encoding pituitary transcription factors vary substantially between populations. The frequency of defects in the genes encoding pituitary transcription factors is extremely low in western European countries, particularly in sporadic patients. The worldwide mutation frequency for the *POU1F1*, *HESX1*, *PROP1*, *LHX3*, and *LHX4* genes is 12.4%, ranging from 11.2% in sporadic to 63% in familial cases. Mutations in *PROP1* are most frequent, particularly in familial cases and certain geographical areas. Therefore, as previously described, genetic analysis for CPHD appears beneficial in familial subjects with CPHD.

In conclusion, patients with CPHD had more severe GHD than those with IGHD. The frequency of defects in the genes encoding pituitary transcription factors is extremely low in Korean patients with congenital hypopituitarism, as is the case in western European countries. Patients with GHD should be evaluated for other endocrine dysfunctions via ophthalmologic examination, sellar MRI, and combined anterior pituitary function tests. Further research is needed to investigate other causative genes involved in pituitary organogenesis or environmental factors.

**ACKNOWLEDGEMENTS**

This study was supported by a grant from the National Research Foundation of Korea, Ministry of Education, Science, and Technology (grant no. 2016M3A9B4915706).

**REFERENCES**

1. Alatzoglou KS, Dattani MT. Genetic forms of hypopituitarism and their manifestation in the neonatal period. Early Hum Dev 2009; 85:705-12.
2. Cushman LJ, Showalter AD, Rhodes SJ. Genetic defects in the development and function of the anterior pituitary gland. Ann Med 2002;34:179-91.
3. Dattani MT. Novel insights into the aetiology and pathogenesis of hypopituitarism. Horm Res 2004;62 Suppl 3:1-13.
4. Bancalari RE, Gregory LC, McCabe MJ, Dattani MT. Pituitary gland development: an update. Endocr Dev 2012;23:1-15.
5. Kelberman D, Rizzotti K, Lovell-Badge R, Robinson IC, Dattani MT. Genetic regulation of pituitary gland development in human and mouse. Endocr Rev 2000;20:790-829.
6. Cohen LE, Radovick S. Molecular basis of combined pituitary hormone deficiencies. Endocr Rev 2002;23:431-42.
7. Parks JS, Brown MR, Hurley DL, Phelps CJ, Wajnerjach MP. Heritable disorders of pituitary development. J Clin Endocrinol Metab 1999;84:4362-70.
8. Kim SS, Kim Y, Shin YL, Kim GH, Kim TU, Yoo HW. Clinical characteristics and molecular analysis of PTF1, PROPI, LHX3, and HESX1 in combined pituitary hormone deficiency patients with abnormal pituitary MR imaging. Horm Res 2003;60:277-83.
9. Mehta A, Hindmarsh PC, Stanhope RG, Brain CE, Preece MA, Dattani MT. Is the thyrotropin-releasing hormone test necessary in the diagnosis of central hypothyroidism in children. J Clin Endocrinol Metab 2003;88:5696-703.
10. Mehta A, Hindmarsh PC, Dattani MT. An update on the biochemi-
cal diagnosis of congenital ACTH insufficiency. Clin Endocrinol (Oxf) 2005;62:307-14.
11. Reynaud R, Gueydan M, Saveau A, Vallette-Kasic S, Enjalbert A, Brue T, et al. Genetic screening of combined pituitary hormone deficiency: experience in 195 patients. J Clin Endocrinol Metab 2006;91:3329-36.
12. de Graaff LC, Argente J, Veenma DC, Drent ML, Uitterlinden AG, Hokken-Koelega AC. PROP1, HESX1, POU1F1, LHX3 and LHX4 mutation and deletion screening and GH1 P89L and IVS3+1/+2 mutation screening in a Dutch nationwide cohort of patients with combined pituitary hormone deficiency. Horm Res Paediatr 2010;73:363-71.
13. Greulich WW, Pyle SI. Radiographic atlas of skeletal development of the hand and wrist. 2nd ed. Stanford: Stanford University Press; 1959.
14. Korean Center for Disease Control and Prevention, The Korean Pediatric Society. Standard growth chart for Korean children and adolescent. Seoul: Kwangmoon Publishing; 2007.
15. Takagi M, Takahashi M, Ohtsu Y, Sato T, Narumi S, Arakawa H, et al. A novel mutation in HESX1 causes combined pituitary hormone deficiency without septo optic dysplasia phenotypes. Endocr J 2016;63:405-10.
16. Argyropoulou M, Perignon F, Brauner R, Brunelle F. Magnetic resonance imaging in the diagnosis of growth hormone deficiency. J Pediatr 1992;120:886-91.
17. McCabe MJ, Alatzoglou KS, Dattani MT. Septo-optic dysplasia and other midline defects: the role of transcription factors: HESX1 and beyond. Best Pract Res Clin Endocrinol Metab 2011;25:115-24.
18. Cohen RN, Cohen LE, Botero D, Yu C, Sagar A, Jurkiewicz M, et al. Enhanced repression by HESX1 as a cause of hypopituitarism and septooptic dysplasia. J Clin Endocrinol Metab 2003;88:4832-9.
19. Dattani MT, Martinez-Barbera JP, Thomas PQ, Brickman JM, Gupta R, Mårtensson IL, et al. Mutations in the homeobox gene HESX1/ Hesx1 associated with septo-optic dysplasia in human and mouse. Nat Genet 1998;19:125-33.
20. Thomas PQ, Dattani MT, Brickman JM, McNay D, Warne G, Zacharin M, et al. Heterozygous HESX1 mutations associated with isolated congenital pituitary hypoplasia and septo-optic dysplasia. Hum Mol Genet 2001;10:39-45.
21. Tajima T, Hattori T, Nakajima T, Okuhara K, Sato K, Abe S, et al. Sporadic heterozygous frameshift mutation of HESX1 causing pituitary and optic nerve hypoplasia and combined pituitary hormone deficiency in a Japanese patient. J Clin Endocrinol Metab 2003;88:45-50.
22. McNay DE, Turton JP, Kelberman D, Woods KS, Brauner R, Papadimitriou A, et al. HESX1 mutations are an uncommon cause of septooptic dysplasia and hypopituitarism. J Clin Endocrinol Metab 2007;92:681-7.
23. De Rienzo F, Mellone S, Bellone S, Babu D, Fusco I, Prodam F, et al. Frequency of genetic defects in combined pituitary hormone deficiency: a systematic review and analysis of a multicentre Italian cohort. Clin Endocrinol (Oxf) 2015;83:849-60.
24. Mehta A, Hindmarsh PC, Mehta H, Turton JP, Russell-Eggitt I, Taylor D, et al. Congenital hypopituitarism: clinical, molecular and neuroradiological correlates. Clin Endocrinol (Oxf) 2009;71:376-82.
25. Bas F, Uyguner ZO, Darendeliler F, Aycan Z, Çetinkaya E, Berberoğlu M, et al. Molecular analysis of PROP1, POU1F1, LHX3, and HESX1 in Turkish patients with combined pituitary hormone deficiency: a multicenter study. Endocrine 2015;49:479-91.